Clinical Trial Update: A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer [Phase 2]

View source ↗

Summary

A placebo-controlled Phase II trial of bone-targeted Radium-223 in symptomatic hormone-refractory prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Prostate Cancer

Drugs mentioned

• Xofigo (radium-223 dichloride)

Snippet

Sponsor: Bayer | Conditions: Prostate Cancer, Neoplasm Metastasis | Phase 2 | Status: COMPLETED